The American Journal of Cardiology (AM J CARDIOL)

Publisher: American College of Cardiology, Elsevier

Journal description

Full Text Online Access, and More, to Paid Subscribers at Published 24 times a year, The American Journal of Cardiology® is an independent journal designed for cardiovascular disease specialists and internists with a subspecialty in cardiology throughout the world. AJC is an independent, scientific, peer-reviewed journal of original articles that focus on the practical, clinical approach to the diagnosis and treatment of cardiovascular disease. AJC has the shortest lag time of all scientific journals (less than 5 months) from receipt of manuscript to publication. Features report on systemic hypertension, methodology, drugs, pacing, arrhythmia, preventive cardiology, congestive heart failure, valvular heart disease, congenital heart disease, and cardiomyopathy. Also included are case reports, brief reports, editorials, readers' comments, and symposia.

Current impact factor: 3.28

Impact Factor Rankings

2015 Impact Factor Available summer 2016
2014 Impact Factor 3.276
2013 Impact Factor 3.425
2012 Impact Factor 3.209
2011 Impact Factor 3.368
2010 Impact Factor 3.68
2009 Impact Factor 3.575
2008 Impact Factor 3.905
2006 Impact Factor 3.015
2005 Impact Factor 3.059
2004 Impact Factor 3.14
2003 Impact Factor 3.059
2002 Impact Factor 2.327
2001 Impact Factor 2.637
2000 Impact Factor 2.762
1999 Impact Factor 2.361
1998 Impact Factor 2.137
1997 Impact Factor 2.402
1996 Impact Factor 2.373
1995 Impact Factor 2.238
1994 Impact Factor 2.253
1993 Impact Factor 2.164
1992 Impact Factor 2.503

Impact factor over time

Impact factor

Additional details

5-year impact 3.35
Cited half-life 9.40
Immediacy index 0.66
Eigenfactor 0.06
Article influence 1.30
Website American Journal of Cardiology, The website
Other titles The American journal of cardiology
ISSN 0002-9149
OCLC 850121
Material type Periodical, Internet resource
Document type Journal / Magazine / Newspaper, Internet Resource

Publisher details


  • Pre-print
    • Author can archive a pre-print version
  • Post-print
    • Author can archive a post-print version
  • Conditions
    • Authors pre-print on any website, including arXiv and RePEC
    • Author's post-print on author's personal website immediately
    • Author's post-print on open access repository after an embargo period of between 12 months and 48 months
    • Permitted deposit due to Funding Body, Institutional and Governmental policy or mandate, may be required to comply with embargo periods of 12 months to 48 months
    • Author's post-print may be used to update arXiv and RepEC
    • Publisher's version/PDF cannot be used
    • Must link to publisher version with DOI
    • Author's post-print must be released with a Creative Commons Attribution Non-Commercial No Derivatives License
    • Publisher last reviewed on 03/06/2015
  • Classification

Publications in this journal

  • [Show abstract] [Hide abstract]
    ABSTRACT: The association between abnormal electrocardiographic P-wave axis with atrial fibrillation (AF) has not been systematically studied in community-based populations. We examined the association between abnormal P-wave axis and AF in 4,274 (41% male, 95% white) participants from the Cardiovascular Health Study (CHS). Axis values between 0º and 75º were considered normal. AF cases were identified from study electrocardiograms (ECGs) and from hospitalization discharge data. During a median follow-up of 12.1 years, a total of 1,274 (30%) participants developed AF. The incidence rate of AF was 26 cases per 1000 person-years for those with abnormal P-wave axis and 24 cases per 1000 person-years for subjects with normal P wave axis. Abnormal P-wave axis was associated with a 17% increased risk of AF (95% Confidence Interval=1.03, 1.33) after adjustment for age, sex, race, education, income, smoking, diabetes, coronary heart disease, stroke, heart failure, heart rate, systolic blood pressure, body mass index, total cholesterol, HDL cholesterol, antihypertensive medications, aspirin, and statins. The results were consistent in subgroup analyses stratified by age, sex, and race. In conclusion, abnormal P-wave axis, a routinely reported electrocardiographic measurement, is associated with an increased risk of AF. This finding suggests a potential role for P-wave axis in AF risk assessment.
    The American Journal of Cardiology 10/2015; DOI:10.1016/j.amjcard.2015.10.013
  • [Show abstract] [Hide abstract]
    ABSTRACT: The prevalence of atrial fibrillation (AF) is increased in hyperthyroidism. The degree to which thyroid hormones affect the outcomes of left atrial (LA) ablation is still unclear. From September 2010 to September 2013, 1095 patients undergoing LA ablation (59.7% paroxysmal AF, 32.3% persistent AF and 8.0% LA tachycardia) had their serum thyroid-stimulating hormone (TSH) and free thyroxine (FT4) levels measured in the 48 hours before the procedure. Patients were followed until they presented the first AF relapse after a blanking period of 3 months. TSH and FT4 were assessed as predictors of arrhythmia relapse and were adjusted for possible confounders. During a mean follow-up of 12.5±7.9 months, 28.9% of patients presented an atrial arrhythmia relapse. TSH was not a predictor of relapse. On the other hand after adjustment, FT4 (median=11.8ng/L and IQR 10.6-14.6 ng/L) remained a predictor of relapse with 15% increase per quartile (HR=1.15, 95%CI 1.03-1.29, p=0.014). In conclusion, FT4 levels influence the success rate of LA ablation procedures, even when in the normal range.
    The American Journal of Cardiology 10/2015; DOI:10.1016/j.amjcard.2015.09.028
  • [Show abstract] [Hide abstract]
    ABSTRACT: Early revascularization is the mainstay of treatment for cardiogenic shock (CS) complicating acute myocardial infarction. However, data on the contemporary trends in management and outcomes of CS complicating non-ST-elevation myocardial infarction (NSTEMI) are limited. We used the 2006 to 2012 Nationwide Inpatient Sample databases to identify patients aged ≥18 years with NSTEMI with or without CS. Temporal trends and differences in coronary angiography, revascularization, and outcomes were analyzed. Of 2,191,772 patients with NSTEMI, 53,800 (2.5%) had a diagnosis of CS. From 2006 to 2012, coronary angiography rates increased from 53.6% to 60.4% in patients with NSTEMI with CS (ptrend <0.001). Among patients who underwent coronary angiography, revascularization rates were significantly higher in patients with CS versus without CS (72.5% vs 62.6%, p <0.001). Patients with NSTEMI with CS had significantly higher risk-adjusted in-hospital mortality (odds ratio 10.09, 95% confidence interval 9.88 to 10.32) as compared to those without CS. In patients with CS, an invasive strategy was associated with lower risk-adjusted in-hospital mortality (odds ratio 0.43, 95% confidence interval 0.42 to 0.45). Risk-adjusted in-hospital mortality, length of stay, and total hospital costs decreased over the study period in patients with and without CS (ptrend <0.001). In conclusion, we observed an increasing trend in coronary angiography and decreasing trend in in-hospital mortality, length of stay, and total hospital costs in patients with NSTEMI with and without CS. Despite these positive trends, overall coronary angiography and revascularization rates remain less than optimal and in-hospital mortality unacceptably high in patients with NSTEMI and CS.
    The American Journal of Cardiology 10/2015; DOI:10.1016/j.amjcard.2015.10.006
  • [Show abstract] [Hide abstract]
    ABSTRACT: The report entitled “PP-116 vortex keratopathy associated with long term use of amiadarone,” written by Altun et al and published in a recent issue of American Journal of Cardiology, was quite interesting.1 Here, we would like to emphasize some relevant points.
    The American Journal of Cardiology 09/2015; 116(5):826. DOI:10.1016/j.amjcard.2015.06.003

  • The American Journal of Cardiology 07/2015; 116(5). DOI:10.1016/j.amjcard.2015.07.002.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Right heart catheterization (RHC) and endomyocardial biopsy are mainstay procedures for patients with heart failure and heart transplantation. Approaches are predominantly neck (internal jugular) or leg (femoral vein). We describe a novel arm (brachial/basilica vein) approach. Over 5.5 years, 1,130 right-sided cardiac procedures in 276 patients were analyzed retrospectively and divided into either neck or arm approach. Comparative analyses of procedural success, time, safety, efficacy, and cost were performed. Patient preference was assessed for those who had both neck and arm approaches. In patients receiving RHC (174 neck and 121 arm cases) and in those receiving RHC + biopsy (594 neck and 141 arm cases), mean elapsed and fluoroscopic times (minutes), respectively, were 60 ± 20 versus 62 ± 19 and 3.43 ± 3.8 versus 4.99 ± 5.2 (RHC neck vs arm, respectively), and 55 ± 19 versus 63 ± 17 and 4.14 ± 3.4 versus 5.22 ± 2.6 (RHC + biopsy neck vs arm, respectively). Procedural complications were low (n = 7, 0.6%) and restricted to the neck approach. Patients surveyed preferred the arm approach. In conclusion, RHC and endomyocardial biopsy through the brachial vein can be performed safely, timely, effectively, and at equivalent cost compared with a neck approach. We advocate that an arm approach be the preferred method for these procedures. Copyright © 2015 Elsevier Inc. All rights reserved.
    The American Journal of Cardiology 06/2015; 116(5). DOI:10.1016/j.amjcard.2015.05.044
  • [Show abstract] [Hide abstract]
    ABSTRACT: Resistin is an adipokine secreted by macrophages and inflammatory cells linked to insulin resistance and inflammation. Leptin is an adipokine regulator of appetite and obesity. Although circulating levels of both have been associated with atherosclerosis, few data have reported their relation to coronary events in the context of statin therapy. This study measured on-statin levels of both resistin and leptin through enzyme-linked immunosorbent assay in a nested case-control cohort (n = 176 cases with coronary death, myocardial infarction, or unstable angina pectoris observed in follow-up matched 1:1 to 176 controls) derived from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 study, a randomized controlled trial of atorvastatin 80 mg/day versus pravastatin 40 mg/day in patients with a recent acute coronary syndrome. Resistin demonstrated a moderate association with high-sensitivity C-reactive protein (hsCRP; Spearman rho = 0.25, p <0.0001). On-statin resistin levels were linked to recurrent coronary events in conditional logistic regression analysis adjusted for additional risk factors including hsCRP and history of diabetes (tertile 3 vs 1 adjusted odds ratio 2.08; 95% confidence interval [CI] 1.04 to 4.19). An additive risk was noted when patients were stratified by resistin and glycated hemoglobin levels. In contrast, leptin levels were associated with obesity, diabetes, triglycerides, and hsCRP (p <0.001 for each) but demonstrated no association with recurrent coronary events (tertile 3 vs 1 adjusted odds ratio 0.72; 95% CI 0.28 to 1.83). In conclusion, on-statin resistin, but not leptin, is an independent marker of residual risk for recurrent coronary events in patients after hospitalization for an acute coronary syndrome. Copyright © 2015 Elsevier Inc. All rights reserved.
    The American Journal of Cardiology 06/2015; 116(5). DOI:10.1016/j.amjcard.2015.05.038

  • The American Journal of Cardiology 06/2015; 116(5). DOI:10.1016/j.amjcard.2015.05.056
  • [Show abstract] [Hide abstract]
    ABSTRACT: As it is controversial whether metabolic syndrome (MetS) affects cardiovascular outcomes in patients who underwent percutaneous coronary intervention (PCI), we investigated the impact of MetS on clinical outcomes in patients who underwent PCI with everolimus-eluting stents (EESs). Patients who underwent PCI with EESs from 2009 to 2013 were included in this single-center, prospective cohort study. A composite event consisted of repeat revascularization, nonfatal myocardial infarction, and cardiac death. Of 903 patients observed for 4.9 years (median 1.8 years), 570 were diagnosed with MetS. The MetS group displayed more severe coronary artery disease and underwent more extensive PCIs than did the non-MetS group. The overall composite event rate was not significantly different between the MetS and the non-MetS group (11.9% vs 13.2%, p = 0.572). Kaplan-Meier survival analysis showed no significant difference in the event-free survival of the composite event between the 2 groups (p = 0.700). A multivariable Cox regression analysis showed that MetS was not associated with the composite event, whereas total stent length, decreased renal function, diabetes, and the absence of abdominal obesity were associated with the composite event. Abdominal obesity was associated with decreased risk of the composite event, alleviating unfavorable clinical outcomes of patients with diabetes in the MetS group. In conclusion, MetS has no impact on the clinical outcomes of patients who underwent PCI with EESs, although the MetS group exhibited more severe coronary artery disease and underwent more extensive PCIs. The paradoxical association between obesity and favorable clinical outcomes may explain this result. Copyright © 2015 Elsevier Inc. All rights reserved.
    The American Journal of Cardiology 06/2015; 116(5). DOI:10.1016/j.amjcard.2015.05.041